

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



吉林省輝南長龍生化藥業股份有限公司

Jilin Province Huinan Changlong Bio-pharmacy Company Limited

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8049)

POLL RESULTS AT THE EXTRAORDINARY GENERAL MEETING HELD ON 2 JUNE 2023 AND SPECIAL DIVIDEND PAYMENT

The board is pleased to announce that an extraordinary general meeting (the “EGM”) held on 2 June 2023, the resolution set out below was duly passed by the Shareholders by way of poll.

Reference is made to the notice of the EGM dated 19 April 2023 (the “Notice”). Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Notice.

POLL RESULTS OF THE EGM

The Board is pleased to announce that at the EGM held on 2 June 2023, the following resolutions were duly passed by way of poll. Hong Kong Registrars Limited, the Company’s registrar in Hong Kong, acted as the scrutineer for the purpose of vote-taking at the EGM. The poll results were as follows:

Special resolution		Number of votes		
		For	Against	Total number of shares voted
1.	To approve the special dividend proposal of the Company.	313,255,000 (100%)	0 (0%)	313,255,000 (100%)

As at the date of the EGM, the Company's total number of issued shares were 560,250,000 Shares (comprising 387,750,000 Domestic Shares and 172,500,000 H Shares). No shareholders were required to abstain from voting at the EGM in respect of the resolutions. Therefore the total number of shares entitling the shareholders to attend and vote for or against the resolutions at the EGM was 560,250,000 shares and there were no shares entitling the shareholders to attend and vote only against the resolutions at the EGM.

As more than two third of the votes were casted in favour of the special resolutions, all resolutions were duly passed.

SPECIAL DIVIDEND PAYMENT

The Company will distribute a special dividend of Renminbi (“**RMB**”) RMB0.50 (including tax) per share in respect of previous financial year. The proposed dividend will be paid to shareholders whose names appeared on the register of shareholders of the Company on 14 June 2023. Dividend payable to the shareholders of H shares (“**H Shareholders**”) will be paid in Hong Kong Dollars (“**HKD**”). The exchange rate between RMB and HKD shall be ascertained on the basis of the average of the middle exchange rates for RMB to HKD as published by the People's Bank of China for the five trading days prior to the date of the EGM.

The Company has appointed Bank of China (Hong Kong) Trustees Limited as payment agent who will pay the special dividend to H Shareholders on or before 30 June 2023. The cheques in relation the dividend will be issued by the payment agent and will be posted by ordinary mail to holders of H shares at their own risk.

The Board comprises five executive directors, being Mr. Zhang Hong, Mr. Zhang Xiao Guang, Mr. Zhao Bao Gang, Mr. Zhang Yi and Mr. Xu Xiang Fu; and one independent non-executive director, Ms. Tian Jie attended the Annual General Meeting and the Extraordinary General Meeting. Other executive director Mr. Wu Guo Wen and two independent nonexecutive directors Gao Qi Pin and Bai Jun Gui did not attend due to their business commitment.

By order of the Board
Jilin Province Huinan Changlong Bio-pharmacy Company Limited
Zhang Hong
Chairman

Jilin Province, the PRC
2 June 2023

As at the date of this announcement, the Board comprises six executive directors, being Zhang Hong, Zhang Xiao Guang, Zhao Bao Gang, Zhang Yi, Xu Xiang Fu and Wu Guo Wen; and three independent non-executive directors, being Gao Qi Pin, Bai Jun Gui and Tian Jie.

This announcement, for which the directors of the Jilin Province Huinan Changlong Bio-pharmacy Company Limited collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to Jilin Province Huinan Changlong Bio-pharmacy Company Limited. The directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this announcement misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the Latest Company Announcements page of the Stock Exchange website at www.hkex.com.hk for at least 7 days from the date of its publication.